PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
The Evolving Role of AR-Targeted Agents in Prostate Cancer: A Window of Opportunity to Maximize Outcomes
Visit https://www.peervoice.com/YJF860 to view the entire programme with slides. After completing “The Evolving Role of AR-Targeted Agents in Prostate Cancer: A Window of Opportunity to Maximize Outcomes”, participants will be able to: Identify the clinical implications of the most recent data evaluating androgen receptor (AR)-targeted agents in metastatic castration-sensitive prostate cancer (mCSPC); Define which patients with mCSPC should be considered for treatment with AR-targeted agents; and Formulate a therapeutic treatment plan for patients with prostate cancer on AR-targeted agents that balances efficacy and safety.